Syndeio Biosciences announced its launch to pioneer precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous system (CNS) diseases. The company's clinical-stage pipeline and proprietary R&D platform are built on cutting-edge discoveries in synapse biology and translational biomarkers, with a mission to transform treatment for patients suffering from major depressive disorder (MDD), Alzheimer's disease, schizophrenia, and other synaptopathies.

Syndeio is building from over $90 million raised to date from a syndicate of leading life science investors, including Catalio Capital Management and Innoviva, and participation from Tenmile, Luson Bioventures, and Palo Santo, with AbbVie and Lilly as strategic shareholders.